Gevokizumab (S-78989) is a humanised monoclonal antibody targeting IL-1β, which blocks IL-1β signalling through allosteric regulation, and can be used for diabetes, cancer, inflammation, and cardiovascular diseases.

Methods:
HeLa cells were treated with 5 nM Gevokizumab for 16 hours to evaluate its inhibitory effect on IL-1β–mediated NF-κB activation; additionally, the effect of Gevokizumab at concentrations ranging from 1.85 to 50 nM on the binding affinity between sIL-1RI and IL-1β was assessed.
Results:
Gevokizumab inhibited IL-1β–induced NF-κB activation and acted as a selective negative allosteric modulator to reduce the binding affinity of sIL-1RI to IL-1β. [1]

Methods:
In a rat carotid denudation model using 3-month-old Sprague-Dawley rats weighing 330–360 g, Gevokizumab was administered intravenously at doses of 1, 10, and 50 mg/kg once daily for 3 consecutive days.
Results:
At day 28, Gevokizumab treatment significantly decreased carotid intima-media thickness (IMT) in the proximal part of the denuded artery, with the 1 mg/kg dose group showing improved endothelial regrowth.[2]